8 drug(s) with this reaction
19,360 total reports
General Physical Health Deterioration has been reported as an adverse reaction across 8 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 19,360 adverse event reports mention general physical health deterioration in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with general physical health deterioration, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have general physical health deterioration listed in their FDA adverse event reports, sorted by report count:
In addition to general physical health deterioration, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
8 drug(s) manufactured by Abbvie Inc have general physical health deterioration listed in their FDA adverse event reports: Humira, ADALIMUMAB, LEVOTHYROXINE SODIUM, VENETOCLAX, PANCRELIPASE, and others.
There are a combined 19,360 reports of general physical health deterioration across 8 Abbvie Inc drug(s) in the FDA adverse event database.